Samsung Biologics Teams Up with AstraZeneca to Propel Commercial Manufacturing

Samsung Biologics and AstraZeneca announced on Monday that they have entered a long-term supply agreement, expected to be valued at approximately $330 million. Under the new deal, Samsung Biologics will offer large-scale commercial manufacturing for drug substance in its Plant 3. In addition, it will support AstraZeneca’s biologics therapeutics.